NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Interesting point. Here is what ChatGpt had to say :
"The Commission on Human Medicines (CHM) is a UK advisory body that provides independent expert advice to ministers on the safety, efficacy, and quality of medicinal products. It operates under the Medicines and Healthcare products Regulatory Agency (MHRA), which is sponsored by the Department of Health and Social Care.




CHM Membership




The CHM comprises a diverse group of professionals, including:







Members are appointed by ministers and are expected to declare any interests in the pharmaceutical industry to maintain transparency and avoid conflicts of interest. 




Association with the NHS




Many CHM members are affiliated with the National Health Service (NHS) in various capacities:







For example, Professor Sir Munir Pirmohamed, the current chair of the CHM, is the NHS Chair of Pharmacogenetics at the University of Liverpool and has served as a consultant physician at the Royal Liverpool University Hospital. 


These associations ensure that CHM’s recommendations are informed by practical clinical experience and align with the needs and realities of the NHS.




Expert Advisory Groups (EAGs)




The CHM is supported by several Expert Advisory Groups (EAGs), each focusing on specific areas such as:







Members of these groups often include NHS professionals who bring frontline clinical insights to the evaluation of medicines.


In summary, the CHM’s composition reflects a blend of academic expertise and practical NHS experience, ensuring that its advice on medicinal products is both scientifically robust and clinically relevant.Yes, several current members of the UK’s Commission on Human Medicines (CHM) hold official positions within the National Health Service (NHS). Their dual roles in both regulatory advisory and clinical practice help ensure that CHM recommendations are grounded in real-world healthcare experience.




Examples of CHM Members with NHS Roles









These appointments reflect the CHM’s commitment to integrating frontline NHS expertise into its regulatory decision-making processes. By involving professionals actively engaged in patient care and clinical research, the CHM ensures that its advice on the safety, efficacy, and quality of medicinal products is both scientifically robust and practically applicable within the NHS framework.